Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 3;36(4):427-433.
doi: 10.1080/08998280.2023.2204535. eCollection 2023.

Trends in hospital admissions and mortality among inflammatory bowel disease patients with substance use disorder: a 10-year United States nationwide analysis

Karina Fatakhova  1 , Pratik Patel  1 , Faisal Inayat  2 , Rubaid Dhillon  3 , Hassam Ali  4 , Sobaan Taj  5 , Gul Nawaz  6 , Arslan Afzal  7 , Attiq Ur Rehman  8 , Muhammad Sohaib Afzal  9 , Rafeh Khan  10 , Rizwan Ishtiaq  11 , Lindsey Jones  12 , Ramona Rajapakse  1
Affiliations

Trends in hospital admissions and mortality among inflammatory bowel disease patients with substance use disorder: a 10-year United States nationwide analysis

Karina Fatakhova et al. Proc (Bayl Univ Med Cent). .

Abstract

Background: Patients with inflammatory bowel disease (IBD) and substance use disorder (SUD) may have worse clinical outcomes. However, data specific to the hospital admission and mortality rates among IBD patients with SUD are scarce. Our objective was to assess trends in admission, healthcare expenses, and mortality for IBD patients with SUD.

Methods: We conducted a retrospective study using the National Inpatient Sample database to analyze SUD (alcohol, opioids, cocaine, and cannabis) among IBD hospitalizations from 2009 to 2019.

Results: A total of 132,894 hospitalizations for IBD had a secondary diagnosis of SUD. Of these patients, 75,172 (57%) were men and 57,696 (43%) were women. The IBD-SUD cohort had a longer length of stay than the non-SUD cohort (P < 0.001). The mean inpatient charges for IBD hospitalizations with SUD increased from $48,699 ± $1374 in 2009 to $62,672 ± $1528 in 2019 (P < 0.001). We found a 159.5% increase in IBD hospitalizations with SUD. The hospitalization rate increased from 3492 per 100,000 IBD hospitalizations in 2009 to 9063 per 100,000 in 2019 (P < 0.001). In-hospital mortality for IBD hospitalizations with SUD increased by 129.6% (from 250 deaths per 100,000 IBD hospitalizations in 2009 to 574 deaths per 100,000 IBD hospitalizations in 2019) (P < 0.001).

Conclusions: Over the last decade, there has been a rise in IBD hospitalizations with SUD. This has resulted in a longer length of stay, higher inpatient charges, and higher mortality rates. Identifying IBD patients potentially at risk for SUD by screening for anxiety, depression, pain, or other factors has become crucial.

Keywords: Alcoholism; hospital admission; human risk factors; inflammatory bowel disease; mortality rate; substance use disorder.

PubMed Disclaimer

Conflict of interest statement

The authors report no funding or conflicts of interests.

Figures

Figure 1.
Figure 1.
Comparative trend analysis of hospital length of stay (LOS) among inflammatory bowel disease hospitalizations with or without substance use disorder.
Figure 2.
Figure 2.
Comparative trend analysis of hospital mean inpatient charges (MIC) among inflammatory bowel disease hospitalizations with or without substance use disorder.
Figure 3.
Figure 3.
Rate of occurrence of substance abuse hospitalization and associated mortality compared with mortality for non-substance abuse hospitalizations for inflammatory bowel disease (IBD) patients. Bars show the rate per 100,000 total IBD hospitalizations. The blue line shows the mortality rate in substance abuse hospitalizations per 100,000 IBD hospitalizations. The yellow line shows the comparative mortality rate in non–substance abuse hospitalizations per 100,000 IBD hospitalizations.
See this image and copyright information in PMC

References

    1. GBD 2017 Inflammatory Bowel Disease Collaborators . The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30. doi: 10.1016/S2468-1253(19)30333-4. - DOI - PMC - PubMed
    1. Singh S, Blanchard A, Walker JR, Graff LA, Miller N, Bernstein CN.. Common symptoms and stressors among individuals with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2011;9(9):769–775. doi: 10.1016/j.cgh.2011.05.016. - DOI - PubMed
    1. Carson HJ, Dudley MH, Knight LD, Lingamfelter D.. Psychosocial complications of Crohn’s disease and cause of death. J Forensic Sci. 2014;59(2):568–570. doi: 10.1111/1556-4029.12314. - DOI - PubMed
    1. Arp L, Jansson S, Wewer V, Burisch J.. Psychiatric disorders in adult and paediatric patients with inflammatory bowel diseases—a systematic review and meta-analysis. J Crohns Colitis. 2022;16(12):1933–1945. doi: 10.1093/ecco-jcc/jjac095. - DOI - PubMed
    1. Tarar ZI, Zafar MU, Farooq U, et al. Burden of depression and anxiety among patients with inflammatory bowel disease: results of a nationwide analysis. Int J Colorectal Dis. 2022;37(2):313–321. doi: 10.1007/s00384-021-04056-9. - DOI - PubMed

LinkOut - more resources